- In January 2024, Fortis Healthcare introduced CAR-T cell therapy across its Bone Marrow Transplant centers in Mohali, Delhi, Gurgaon, Noida, Mumbai, and Bangalore. This groundbreaking therapy enhances treatment options for blood cancers such as leukemia and lymphoma, utilizing advanced cellular technology to improve patient outcomes. The launch reinforces Fortis Healthcare’s leadership in the global bone marrow market, expanding access to cutting-edge therapies in India
- In September 2022, Scopio Labs introduced the Full-Field Bone Marrow Aspirate (FF-BMA) application, a digital workflow solution designed to streamline bone marrow aspirate scanning and analysis. This innovation enhances diagnostic efficiency and accuracy, addressing the rising demand for automated tools in bone marrow diagnostics. By integrating AI-powered imaging, the FF-BMA application strengthens the capabilities of transplant centers and laboratories worldwide
- In June 2022, the US FDA granted 510(k) approval for the MAXX-BMC bone marrow aspirate concentration system, developed by Royal Biologics. This system enables optimal sample collection of concentrated bone marrow aspirate at point-of-care settings, enhancing efficiency in orthopedic and sports medicine procedures. Featuring patented Lead Screw technology, MAXX-BMC improves stem cell concentration and accelerates bone growth and tissue regeneration
- In February 2022, Celgene and Bluebird Bio announced a collaboration to develop and commercialize CAR T-cell therapies for blood cancers. By combining Celgene’s expertise in hematology and oncology with Bluebird Bio’s CAR T-cell technology, the partnership aims to advance treatment options for bone marrow-related disorders. This collaboration strengthens their competitive position in the global bone marrow market, accelerating innovation and market reach
- In February 2022, Gilead Sciences and Kite Pharma partnered to develop and commercialize CAR T-cell therapies for blood cancers. This collaboration leverages Gilead’s global commercial expertise and Kite Pharma’s specialized CAR T-cell technology to enhance bone marrow transplant therapies. The partnership aims to advance treatment efficacy and expand access to innovative therapies worldwide
